Business
Nanopore partners with govt on covid-19 test
Nanopore partners with govt on covid-19 test.
About this update from Ip Group Plc
[{"type":"text","content":"\n \n \n RNS Number : 8463U\n IP Group PLC\n 03 August 2020\n \n \n \n \n \n \n \n \n FOR RELEASE ON\n \n \n \n \n 03 August 2020\n \n \n \n \n \n \n \n \n \n \n IP Group plc - Portfolio company Oxford Nanopore Technologies \n \n partners with UK Government to roll out LamPORE, a new generation of COVID-19 test\n \n \n · \n \n Ground-breaking British technology will initially provide hundreds of thousands of fast, accurate, low-cost COVID-19 tests under new agreement with the UK Government, with the potential to build to millions of tests per month. Results can be obtained in under two hours.\n \n \n \n \n \n \n IP Group plc (LSE: IPO) (\"IP Group\" or \"the Group\" or \"the Company\"), the developer of intellectual property-based businesses, notes that its portfolio company Oxford Nanopore Technologies Limited (\"Oxford Nanopore\"), has announced an agreement with the UK's Department of Health and Social Care, to roll out its novel LamPORE test. This will support the UK's efforts to manage the continued reduction of COVID-19 and containment of new cases, now and through the winter cold and flu season.\n \n \n \n \n \n Under the agreement, an initial 450k LamPORE SARS-CoV-2 tests will be made available for use by a number of NHS testing laboratories. As well as providing a large number of tests for existing labs, the programme will help the UK to understand the different use cases for the technology, for example the potential asymptomatic screening of frontline staff. \n \n \n \n \n \n \n Alan Aubrey, Chief Executive of IP Group\n \n , said: \"The roll-out of LamPORE, the company's first diagnostic assay, is a significant development for Oxford Nanopore and in the battle against \n COVID-19 in the UK. We are proud that Oxford Nanopore has been supplying countries all over the world with sequencing capability throughout this pandemic to help support the response to the crisis.\"\n \n \n \n \n \n Since the first emergence of the virus, Oxford Nanopore's rapid, portable sequencing technology has been used extensively for COVID-19 epidemiology and scientific research.\n \n \n \n \n \n IP Group holds an undiluted beneficial stake of 15.8% in Oxford Nanopore Technologies.\n \n \n \n \n \n The full announcement follows....